Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.36 |
| ▸ | METAP2 | P50579 | 6/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMURF2 | Q9HAU4 | 1/20 | 0.31 |
| ▸ | SMURF1 | Q9HCE7 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5576963 | 0.93 | DRD2 (0.35) | DRD2SLC6A3METAP2SLC6A2SCN9A | |
| SCHEMBL5335228 | 0.90 | DRD2 (0.35) | DRD2SLC6A3METAP2SLC6A2SCN9A | |
| SCHEMBL5577157 | 0.87 | SLC2A1 (0.37) | DRD2SLC6A3METAP2TDP1SLC6A2 | |
| SCHEMBL5314350 | 0.87 | PTGS1 (0.36) | DRD2SLC6A3TDP1SLC6A2 | |
| Hydrochloric Acid SCHEMBL5310762 | 0.86 | SLC2A1 (0.36) | DRD2SLC6A3METAP2TDP1SLC6A2 | |
| SCHEMBL14529641 | 0.85 | DRD2 (0.34) | DRD2SLC6A3METAP2SLC6A2SCN9A | |
| SCHEMBL5576790 | 0.83 | DRD2 (0.36) | DRD2SLC6A3METAP2SLC6A2SCN9A | |
| SCHEMBL5576944 | 0.81 | ACHE (0.39) | TDP1HTT | |
| SCHEMBL5576954 | 0.80 | PTGS1 (0.34) | DRD2SLC6A3SLC6A2SCN9A | |
| SCHEMBL14513381 | 0.79 | PTGS1 (0.35) | DRD2SLC6A3SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099986-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099986-A1 | Preventives/remedies for urinary disturbance | REN, GLS, ATP6V1B1 | DRD2 1113/4885SLC6A3 594/4885METAP2 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.